Clinical trial · Observational
Genomic Profiling of Pancreatic Cystic Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cyst | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NA (No intervention) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing
- timeFrame
- Through study completion, an average of 3 years
- description
- Genetic variants showing significant differences between pancreatic cysts with high-grade dysplasia or invasive cancer and the remaining pancreatic cysts, assessed through next-generation sequencing
Secondary outcomes (1)
- measure
- Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing
- timeFrame
- Through study completion, an average of 3 years
- description
- Genetic variants indicating significant differences between mucinous and serous cysts, as evaluated through next-generation sequencing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection * Patients who gave written informed consent Exclusion Criteria: * Anyone who has not signed a written consent form. * Patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)
References
Publications (0)
Data not yet available